Literature DB >> 3092105

A novel VH to VHDJH joining mechanism in heavy-chain-negative (null) pre-B cells results in heavy-chain production.

M Reth, P Gehrmann, E Petrac, P Wiese.   

Abstract

During B-cell development, the VH genes of immunoglobulin heavy (H) chains are assembled from three different germline components: the variable (VH) segment, the diversity (D) segment and the joining (JH) segment. The joining between two segments involves the recognition of conserved nonamer-heptamer sequences bordering each segment, double-stranded cuts at the heptamer-segment border, and the re-ligation of the two segment ends which have frequently been modified by the deletion and addition of nucleotides. The flexibility of the joint increases VHDJH variability. However, it also results in many pre-B cells which do not produce immunoglobulin H chains and have non-functional VHDJH complexes carrying the VH and JH coding sequences in different reading frames. We show here that such 'null cells' are not dead-end products of the B-cell developmental pathway but can perform a novel VH to VHDJH joining using a 5' VH segment to replace the VH sequence of the VHDJ-H complex. This process can result in the generation of a VHDJ+H complex and the subsequent expression of an immunoglobulin heavy chain.

Mesh:

Substances:

Year:  1986        PMID: 3092105     DOI: 10.1038/322840a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  94 in total

1.  Receptor revision of immunoglobulin heavy chain genes in human MALT lymphomas.

Authors:  D Lenze; A Greiner; C Knörr; I Anagnostopoulos; H Stein; M Hummel
Journal:  Mol Pathol       Date:  2003-10

2.  Diversification of the Ig variable region gene repertoire of synovial B lymphocytes by nucleotide insertion and deletion.

Authors:  Yasushi Miura; Charles C Chu; David M Dines; Stanley E Asnis; Richard A Furie; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

3.  Immunoglobulin heavy chain gene rearrangement involving V-V region recombination.

Authors:  M Deane; J D Norton
Journal:  Nucleic Acids Res       Date:  1990-03-25       Impact factor: 16.971

Review 4.  Allelic exclusion of immunoglobulin genes: models and mechanisms.

Authors:  Christian Vettermann; Mark S Schlissel
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

5.  Rearrangement of variable region T cell receptor gamma genes in acute lymphoblastic leukemia. V gamma gene usage differs in mature and immature T cells.

Authors:  J Hara; S H Benedict; K Yumura; K Ha-Kawa; E W Gelfand
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

6.  No evidence for the use of DIR, D-D fusions, chromosome 15 open reading frames or VH replacement in the peripheral repertoire was found on application of an improved algorithm, JointML, to 6329 human immunoglobulin H rearrangements.

Authors:  Line Ohm-Laursen; Morten Nielsen; Stine R Larsen; Torben Barington
Journal:  Immunology       Date:  2006-10       Impact factor: 7.397

7.  Distinct DNA sequence and structure requirements for the two steps of V(D)J recombination signal cleavage.

Authors:  D A Ramsden; J F McBlane; D C van Gent; M Gellert
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

8.  Assessing the pathogenic potential of the V(D)J recombinase by interlocus immunoglobulin light-chain gene rearrangement.

Authors:  S N Bailey; N Rosenberg
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

9.  Contribution of V(H) replacement products to the generation of anti-HIV antibodies.

Authors:  Hongyan Liao; Jun-tao Guo; Miles D Lange; Run Fan; Michael Zemlin; Kaihong Su; Yongjun Guan; Zhixin Zhang
Journal:  Clin Immunol       Date:  2012-11-15       Impact factor: 3.969

10.  Conserved cryptic recombination signals in Vkappa gene segments are cleaved in small pre-B cells.

Authors:  Anne E Lieberman; Masayuki Kuraoka; Marco Davila; Garnett Kelsoe; Lindsay G Cowell
Journal:  BMC Immunol       Date:  2009-06-25       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.